New antiarrhythmic drugs for atrial fibrillation: Focus on dronedarone and vernakalant

Journal of Interventional Cardiac Electrophysiology

Volumn 23, Issue 1, 2008, Pages 7-14

  Camm, A John ^a   Savelieva, Irina ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Atrial repolarization delaying agents; Dronedarone; Gap junction modifiers; Rhythm control; Rotigaptide; Vernakalant

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ADENOSINE RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; AMILORIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ATI 2042; AVE 1231; AZIMILIDE; CELIVARONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEKALANT; NIP 141; NIP 142; OMEGA 3 FATTY ACID; PIRFENIDONE; PM 101; QUINIDINE; RANOLAZINE; ROTIGAPTIDE; S 0100176; S 20951; S 9947; SELODENOSON; SPIDER VENOM; SSR 149744C; TECADENOSON; TEDISAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT; XEND 0101;

AGING; ANTIARRHYTHMIC ACTIVITY; BRADYCARDIA; CATHETER ABLATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GAP JUNCTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; HYPOTHYROIDISM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; SINUS RHYTHM; SITTING; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

AMIODARONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FUNCTION; HUMANS; PYRROLIDINES;

EID: 53849133772     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-008-9269-3     Document Type: Review

References (33)

1. A. J. Camm I. Savelieva G. Y. Lip 2007 Rate control in the medical management of atrial fibrillation Heart 93 35 38
2. M. Jahangiri G. Weir K. Mandal I. Savelieva J. Camm 2006 Current strategies in the management of atrial fibrillation Annals of Thoracic Surgery 82 357 364
3. I. Savelieva J. Camm 2008 Update on atrial fibrillation: Part II Clinical Cardiology 31 102 108
4. P. Touboul J. Brugada A. Capucci H. J. Crijns N. Edvardsson S. H. Hohnloser 2003 Dronedarone for prevention of atrial fibrillation: a dose-ranging study European Heart Journal 24 1481 1487
5. B. N. Singh S. J. Connolly H. J. Crijns D. Roy P. R. Kowey A. Capucci 2007 Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter New England Journal of Medicine 357 987 999
6. S. H. Hohnloser B. N. Singh 2005 Dronedarone significantly decrease the combined endpoint of hospitalization and death in patients with atrial fibrillation Circulation 112 Supplement II 326 328
7. P. Gautier M. Serre S. Cosnier-Pucheu L. Djandjighian A. Roccon J. M. Herbert 2005 In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias Journal of Cardiovascular Pharmacology 45 125 135
8. P. R. Kowey E. M. Aliot A. Capucci S. J. Connolly H. J. Crijns S. H. Hohnloser 2007 Placebo-controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter Heart Rhythm 4 Supplement 5S S72 abstract
9. Kowey, P., Eliot, E. M., Capucci, A., Connolly, S. J, Crijns, H., Hohnloser, S. H., et al. (2008). Placebo-controlled double-blind dose-ranging study of the efficacy and safety of celivarone for the prevention of ventricular arrhythmia-triggered ICD interventions. Journal of the American College of Cardiology, 51(Supplement A2), (abstract).
10. E. L. Pritchett R. L. Page S. J. Connolly S. R. Marcello D. J. Schnell W. E. Wilkinson 2000 Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response Journal of the American College of Cardiology 36 794 802
11. A. J. Camm C. M. Pratt P. J. Schwartz H. R. Al-Khalidi M. J. Spyt M. J. Holroyde 2004 Mortality in patients with recent myocardial infarction: A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification Circulation 109 990 996
12. C. M. Pratt S. N. Singh H. R. Al-Khalidi J. M. Brum M. J. Holroyde S. R. Marcello 2004 The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial Journal of the American College of Cardiology 43 1211 1216
13. E. L. Pritchett P. Kowey S. Connolly R. L. Page C. Kerr W. E. Wilkinson 2006 Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm American Heart Journal 151 1043 1049
14. F. Lombardi M. Borggrefe W. Ruzyllo B. Luderitz A-COMET-II Investigators 2006 Azimilide vs placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial European Heart Journal 27 2224 2231
15. C. R. Kerr S. J. Connolly P. Kowey R. L. Page E. L. Pritchett M. Y. Ruda 2006 Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease American Journal of Cardiology 98 215 218
16. S. H. Hohnloser P. Dorian M. Straub K. Beckmann P. Kowey 2004 Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter Journal of the American College of Cardiology 44 99 104
17. D. Roy B. H. Rowe I. G. Stiell B. Coutu J. H. Ip D. Phaneuf 2004 A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation Journal of the American College of Cardiology 44 2355 2361
18. D. Roy C. M. Pratt C. Torp-Pedersen D. G. Wyse E. Toft S. Juul-Moller 2008 Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial Circulation 117 1518 1525
19. D. Roy C. Pratt S. Juul-Møller E. Toft D. G. Wyse T. Nielsen 2006 Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: Results of a phase III, randomized, placebo-controlled, multicenter trial Journal of the American College of Cardiology 47 Supplement A 10A abstract
20. CARDIOME PHARMA CORP. Retrieved February 29, 2008 from http://www.cardiome.com/VernakalantOral.php.
21. Pharmaceutical BUSINESS Review. Retrieved April 12, 2008 from http://www.pharmaceutical-business-review.com/article_news.asp?guid= CF004A79-C1D8-45E3-A431-B29EE1B34D41.
22. Kur/Kv1.5 blocker in dogs Heart Rhythm 2 Supplement 1S S180 abstract
23. L. Polontchouk J. A. Haefliger B. Ebelt T. Schaefer D. Stuhlmann U. Mehlhorn 2001 Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria Journal of the American College of Cardiology 38 883 891
24. U. Wetzel A. Boldt J. Lauschke J. Weigl P. Schirdewahn A. Dorszewski 2005 Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies Heart 91 166 170
25. A. Shiroshita-Takeshita M. Sakabe K. Haugan J. K. Hennan S. Nattel 2007 Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs Circulation 115 310 318
26. F. Bode F. Sachs M. R. Franz 2001 Tarantula peptide inhibits atrial fibrillation Nature 409 35 36
27. A. Burashnikov J. M. Di Diego A. C. Zygmunt L. Belardinelli C. Antzelevitch 2007 Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine Circulation 116 1449 1457
28. I. Savelieva A. J. Camm 2004 Atrial fibrillation and heart failure: Natural history and pharmacological treatment Europace 5 Supplement 1 S5 S19
29. K. W. Lee T. H. Everett D. Rahmutula J. M. Guerra E. Wilson C. Ding 2006 Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure Circulation 114 1703 1712
30. J. Dernellis M. Panaretou 2004 Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation European Heart Journal 25 1100 1117
31. M. Jahangiri A. J. Camm 2007 Do corticosteroids prevent atrial fibrillation after cardiac surgery Nature Clinical Practice Cardiovascular Medicine 4 592 593
32. I. Savelieva J. Camm 2008 Statins and polyunsaturated fatty acids for treatment of atrial fibrillation Nature Clinical Practice Cardiovascular Medicine 5 30 41
33. G. Patti M. Chello D. Candura V. Pasceri A. D'Ambrosio E. Covino 2006 Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study Circulation 114 1455 1461